argenex (ARGX) Stock Price, News & Analysis

Company Overview

argenx SE is a global biopharmaceutical company focused on developing and commercializing antibody-based medicines for patients with severe autoimmune diseases. The company’s research is centered on its antibody engineering technologies, including the SIMPLE Antibody platform and NHance technology, which are designed to identify and enhance therapeutic antibodies.

argenx’s leading product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce disease-causing immunoglobulin G antibodies. VYVGART and its subcutaneous formulation, VYVGART Hytrulo, are used in the treatment of generalized myasthenia gravis in various markets. The products have also expanded into chronic inflammatory demyelinating polyneuropathy, subject to regulatory approvals in applicable jurisdictions. The company is studying efgartigimod in additional autoimmune conditions.

Founded in 2008, argenx is headquartered in Ghent, Belgium, and maintains operations in the United States and other international markets. Its medicines are available in multiple geographies through regulatory approvals and commercial partnerships. Tim Van Hauwermeiren serves as the company’s chief executive officer.

Key Stats

• Today's Range: $986.90 to $999.97
• 50-Day Range: $830.79 to $1,058.90
• 52-Week Range: $661.85 to $1,072.75
• Volume: 21,621 shs
• Average Volume: 339,242 shs
• Market Capitalization: $62.54 billion
• P/E Ratio: 38.38
• Dividend Yield: N/A
• Price Target: $1,158.61
• Consensus Rating: Moderate Buy

argenex Stock Analysis - MarketRank™

argenex scored higher than 92% of companies evaluated by MarketBeat, and ranked 38th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

argenex has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 17 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

argenex has a consensus price target of $1,158.61, representing about 15.6% upside from its current price of $1,002.31.

Amount of Analyst Coverage

argenex has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 27.94%

Earnings Growth

Earnings for argenex are expected to grow by 27.94% in the coming year, from $29.13 to $37.27 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of argenex is 38.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of argenex is 38.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.78.

Price to Earnings Growth Ratio

argenex has a PEG Ratio of 1.04. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

argenex has a P/B Ratio of 8.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.97% of the float of argenex has been sold short.

Short Interest Ratio / Days to Cover

argenex has a short interest ratio ("days to cover") of 4.35.

Change versus previous month

Short interest in argenex has recently decreased by 9.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

argenex does not currently pay a dividend.

Dividend Growth

argenex does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.62

News Sentiment

argenex has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for argenex this week, compared to 8 articles on an average week.

Search Interest

19 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 90% compared to the previous 30 days.

MarketBeat Follows

8 people have added argenex to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, argenex insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.43% of the stock of argenex is held by insiders.

Percentage Held by Institutions

60.32% of the stock of argenex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/21/2026
• Today: 9/10/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARGX
• Previous Symbol: NASDAQ:ARGX
• CIK: 1697862
• Web: www.argenx.com
• Phone: (176) 303-0488
• Fax: N/A
• Employees: 1,863
• Year Founded: 2008

Price Target and Rating

• Average Price Target for argenex: $1,158.61
• High Price Target: $1,415.00
• Low Price Target: $910.00
• Potential Upside/Downside: +15.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $26.04
• Trailing P/E Ratio: 38.49
• Forward P/E Ratio: 34.41
• P/E Growth: 1.04
• Net Income: $1.29 billion
• Net Margins: 32.19%
• Pretax Margin: 32.80%
• Return on Equity: 43.59%
• Return on Assets: 36.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.12
• Quick Ratio: 4.89

Sales & Book Value

• Annual Sales: $4.25 billion
• Price / Sales: 14.76
• Cash Flow: $21.23 per share
• Price / Cash Flow: 47.21
• Book Value: $118.34 per share
• Price / Book: 8.47

Miscellaneous

• Outstanding Shares: 62,560,000
• Free Float: 61,041,000
• Market Cap: $62.70 billion
• Optionable: Optionable
• Beta: 0.47